International Isotopes SEC Filings

International Isotopes Inc. (INIS) reported Q3 2025 results with sale of product of $3,277,816 and a net loss of $203,601. For the nine months ended September 30, 2025, sale of product was $10,172,036 and net loss was $477,080. Gross margin held near 59% in Q3 as operating expenses declined 7% year over year.

The company advanced its planned divestiture of the Fluorine Products and de‑conversion assets, noting total cash consideration of $12.5 million if the deal closes by the Outside Date of March 31, 2026. On September 30, 2025, INIS and the buyer submitted an application to the NRC to transfer the license; closing remains subject to financing and regulatory approvals.

Theranostics revenue fell on a temporary supplier outage and partial account loss, while Calibration & Reference grew; management cites an additional approved supplier from September. Cash and cash equivalents were $1,651,548 with restricted cash of $1,477,685. INIS disclosed an FDA inspection in April resulting in an OAI; corrective actions have been submitted and manufacturing continues pending reinspection.

International Isotopes Inc. (INIS) approved a new employment agreement for CEO and President Shahe Bagerdjian. The term runs from July 18, 2025 to July 18, 2030, with an initial base salary of $314,000 and automatic 5% annual increases. He may receive additional $50,000 salary increases as quarterly revenue reaches $3.75M, $6.25M, $12.5M, $18.75M, and $25M, excluding one-time other income items.

The agreement grants 37,500,000 RSUs, vesting after the share price is at or above $0.10 (2.5M), $0.15 (5.0M), $0.20 (7.5M), $0.25 (10.0M), and $0.30 (12.5M) for 60 consecutive days and subject to a tax‑withholding cash condition or six months after the trigger date. Unvested RSUs accelerate upon termination without cause or immediately before a change of control while in good standing. He remains eligible for annual cash bonuses set by the Board.

Governance updates: Dr. Duke W. Fu was appointed an independent director and to the audit committee; he will receive 250,000 RSUs per annual term (vesting commencement July 11, 2026). The Board amended bylaws to limit special-meeting business to noticed items, add advance notice for business and director nominations, permit advisory directors, allow shareholder action by less than unanimous written consent, and add indemnification and insurance provisions.

International Isotopes Inc. (INIS) updated leadership agreements and corporate governance. The company entered a new employment agreement with CEO and President Shahe Bagerdjian, effective July 18, 2025, through July 18, 2030, with automatic one-year renewals. His initial annual base salary is $314,000 with automatic 5% yearly increases and potential $50,000 step-ups tied to quarterly revenue milestones at $3.75M, $6.25M, $12.5M, $18.75M, and $25M.

Bagerdjian received 37,500,000 RSUs vesting upon sustained share-price hurdles of $0.10, $0.15, $0.20, $0.25, and $0.30 and specified cash/withholding conditions; unvested RSUs vest upon termination without cause or immediately prior to a change of control if in good standing. A prior 6,500,000 RSU grant remains, with 3,000,000 vesting on April 17, 2026.

The Board appointed Dr. Duke W. Fu as an independent director and audit committee member; compensation includes 250,000 RSUs per annual term starting July 11, 2026. Amended bylaws add advance notice procedures for business and director nominations, clarify special meeting scope and scheduling, permit advisory directors, allow shareholder action by less than unanimous written consent, and add indemnification and insurance provisions.

International Isotopes Inc. (INIS) director reported an equity grant. On 10/10/2025, the insider acquired 250,000 shares of common stock at $0, recorded as a grant of restricted stock units, with each unit representing the right to receive one INIS share. Following the transaction, the insider beneficially owned 1,000,000 shares, held directly.

International Isotopes Inc. (INIS) reported a director received a stock option grant. On 10/10/2025, the reporting person was awarded 500,000 stock options at an exercise price of $0.06 per share, recorded with transaction code A.

The options are first exercisable on 07/11/2026 and expire on 10/10/2035. Following this transaction, the reporting person beneficially owned 500,000 derivative securities, held directly.

International Isotopes Inc. (INIS) reported an insider transaction on a Form 4. A reporting person who is both a Director and 10% Owner was granted a stock option to purchase 500,000 shares of common stock at an exercise price of $0.06 per share on 10/10/2025 (transaction code A).

The option becomes exercisable on 07/11/2026 and expires on 10/10/2035. Following the transaction, the insider beneficially owned 500,000 derivative securities, held directly.

International Isotopes Inc. (INIS) reported an insider equity award on Form 4. President & CEO and director Shahe Bagerdjian received 37,500,000 restricted stock units (RSUs) on October 9, 2025 under the company’s Amended and Restated 2015 Incentive Plan.

Each RSU represents a contingent right to receive one share of INIS common stock. The RSUs vest based on milestones tied to the company’s share price and available cash. Following the transaction, the filing shows 37,500,000 derivative securities beneficially owned, held directly, with a stated price of $0 for the RSUs.